Apellis Pharmaceuticals, Inc. (APLS)

Trade APLS now with
12/16/2022 7:43:15 AM Apellis Submits MAA To European Medicines Agency For Pegcetacoplan For Geographic Atrophy
11/18/2022 7:08:37 AM Apellis Announces FDA Acceptance Of NDA Amendment And New PDUFA Date Of Feb 26, 2023 For Pegcetacoplan
11/12/2021 7:53:17 AM Apellis Pharma Plans To Submit NDA For Intravitreal Pegcetacoplan In The First Half Of 2022
10/15/2021 7:23:27 AM Apellis And Sobi Receive Positive CHMP Opinion For Aspaveli For Paroxysmal Nocturnal Hemoglobinuria
5/25/2021 7:58:02 AM Swedish Orphan Biovitrum Reports Positive Top-line Results From Phase 3 PRINCE Study Of Pegcetacoplan
4/12/2018 9:52:55 AM B. Riley FBR Cuts Apellis Pharmaceuticals, Inc. (APLS) To Neutral From Buy With $27 Price Target